Ya-Mei Bai1, Wen-Fei Chiou2, Tung-Ping Su3, Cheng-Ta Li3, Mu-Hong Chen4. 1. Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: ymbi@mail2000.com.tw. 2. National Research Institute of Chinese Medicine, Taipei, Taiwan; Institute of Life Science, National Taitung University, Taitung, Taiwan; Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. 3. Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan. 4. Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: More than two-thirds of depressed patients complain of somatic and pain symptoms, which are frequently regarded as a psychological reaction. Although there is a growing body of evidence showing that depression is related to immune abnormalities, few studies have investigated the association between inflammatory cytokines and somatic/pain symptoms. METHOD: Patients with depressive disorder but without any medical disorders, and age/gender/body mass index (BMI)-matched healthy subjects were enrolled. All the subjects completed the self-rating scales of the Beck Depression Inventory-II and the Depression and Somatic Symptoms Scale, which was comprised of depressive, somatic, and pain subscales. Pro-inflammatory cytokines, including C-reactive protein (CRP), interleukin-2 receptor (sIL-2R), soluble interleukin 6 receptor (sIL-6R), soluble TNF-receptors (sTNF-R), soluble P-selectin (sP-selectin), monocyte chemotactic protein-1 (MCP-1), and adiponectin, were assessed by enzyme-linked immunosorbent assays. RESULTS: In all, 109 patients with depressive disorder and 126 normal controls were enrolled. The patients with depressive disorder had significantly more severe depression, somatic and pain symptoms (all p<0.001), and higher levels of sIL-2R (p<0.0001), sTNF-R (p<0.001), and sP-selectin (p=0.005) than the normal control group. Using multivariate regression analysis with controlling of age, gender, BMI, and other pro-inflammatory cytokines, sIL-2R was the most significant predictor for depressive symptoms (p<0.0001); with further controlling of severity of depressive symptom, sP-selectin was the only predictor for somatic (p=0.002) and pain (p=0.059) symptoms. CONCLUSION: The elevated sP-selectin associated with somatic symptoms in depression, may indicate early micro-vascular changes occur subtly, and provide neurobiological evidence for somatic and pain symptom in depression.
BACKGROUND: More than two-thirds of depressedpatients complain of somatic and pain symptoms, which are frequently regarded as a psychological reaction. Although there is a growing body of evidence showing that depression is related to immune abnormalities, few studies have investigated the association between inflammatory cytokines and somatic/pain symptoms. METHOD:Patients with depressive disorder but without any medical disorders, and age/gender/body mass index (BMI)-matched healthy subjects were enrolled. All the subjects completed the self-rating scales of the Beck Depression Inventory-II and the Depression and Somatic Symptoms Scale, which was comprised of depressive, somatic, and pain subscales. Pro-inflammatory cytokines, including C-reactive protein (CRP), interleukin-2 receptor (sIL-2R), soluble interleukin 6 receptor (sIL-6R), soluble TNF-receptors (sTNF-R), soluble P-selectin (sP-selectin), monocyte chemotactic protein-1 (MCP-1), and adiponectin, were assessed by enzyme-linked immunosorbent assays. RESULTS: In all, 109 patients with depressive disorder and 126 normal controls were enrolled. The patients with depressive disorder had significantly more severe depression, somatic and pain symptoms (all p<0.001), and higher levels of sIL-2R (p<0.0001), sTNF-R (p<0.001), and sP-selectin (p=0.005) than the normal control group. Using multivariate regression analysis with controlling of age, gender, BMI, and other pro-inflammatory cytokines, sIL-2R was the most significant predictor for depressive symptoms (p<0.0001); with further controlling of severity of depressive symptom, sP-selectin was the only predictor for somatic (p=0.002) and pain (p=0.059) symptoms. CONCLUSION: The elevated sP-selectin associated with somatic symptoms in depression, may indicate early micro-vascular changes occur subtly, and provide neurobiological evidence for somatic and pain symptom in depression.
Authors: Harris A Eyre; Tracy Air; Alyssa Pradhan; James Johnston; Helen Lavretsky; Michael J Stuart; Bernhard T Baune Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2016-02-20 Impact factor: 5.067
Authors: Marie Lou Camara; Frances Corrigan; Emily J Jaehne; Magdalene C Jawahar; Helen Anscomb; Bernhard T Baune Journal: Neuropsychopharmacology Date: 2014-08-08 Impact factor: 7.853
Authors: Alan M Rathbun; Michelle D Shardell; Elizabeth A Stuart; Ann L Gruber-Baldini; Denise Orwig; Glenn V Ostir; Gregory E Hicks; Marc C Hochberg; Jay Magaziner Journal: Int J Geriatr Psychiatry Date: 2018-02-26 Impact factor: 3.485
Authors: Faisal Akram; Claudia Gragnoli; Uttam K Raheja; Soren Snitker; Christopher A Lowry; Kelly A Stearns-Yoder; Andrew J Hoisington; Lisa A Brenner; Erika Saunders; John W Stiller; Kathleen A Ryan; Kelly J Rohan; Braxton D Mitchell; Teodor T Postolache Journal: J Psychiatr Res Date: 2020-01-02 Impact factor: 4.791
Authors: Tyler Reed Bell; Caitlin N Pope; Brian Downer; Cheyanne Barba; Michael Crowe Journal: Neuropsychol Dev Cogn B Aging Neuropsychol Cogn Date: 2021-06-30